Nature13d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Yahoo Finance13d
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Silence can speak volumes. That silence is even louder coming from Novo Nordisk, Europe’s most valuable company, which is still reeling from disappointing weight-loss drug results in December on ...
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
Mint14d
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...
Free Malaysia Today14d
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...
AOL14d
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
In December, shares in Novo Nordisk plunged after its newest weight loss drug, CagriSema, disappointed in weight loss trials. The GLP-1-based drug only helped participants shed an average of 22.7% ...
Fortune14d
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Novo Nordisk is set to release annual results on Wednesday. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our ...